Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Procarbazine

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    25 result(s) found for: Procarbazine. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2006-000995-33 Sponsor Protocol Number: EuroNet-PHL-C1 Start Date*: 2006-12-13
    Sponsor Name:Martin-Luther-University Halle-Wittenberg
    Full Title: EuroNet-Paediatric Hodgkin’s Lymphoma Group First international Inter-Group Study for classical Hodgkin’s Lymphoma in Children and Adolescents
    Medical condition: 1st and 2nd line therapy for childhood Hodgkin’s lymphoma shall be further optimised to avoid over-treatment and decrease long-term complications.
    Disease: Version SOC Term Classification Code Term Level
    8.1 10025319 Lymphomas Hodgkin's disease HLGT
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) CZ (Completed) GB (Completed) SE (Completed) AT (Completed) FR (Completed) IE (Completed) ES (Completed) DK (Completed) PL (Completed) BE (Completed) NL (Completed) SI (Completed)
    Trial results: View results
    EudraCT Number: 2007-003187-22 Sponsor Protocol Number: Uni-Koeln-908 Start Date*: 2008-04-17
    Sponsor Name:University of Cologne
    Full Title: HD18 for advanced stages in Hodgkins Lymphoma
    Medical condition: Hodgkin´s lymphoma advanced stage
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed) CZ (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2006-006084-23 Sponsor Protocol Number: P060239 Start Date*: 2007-05-28
    Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
    Full Title: Etude multicentrique, randomisée , de phase II évaluant l'association méthotrexate et témozolomide (MT) à l'association méthotrexate, procarbazine, vincristine et cytarabine (MPV-A) dans le traitem...
    Medical condition: Lymphome Primitif du Système Nerveux Central (LPSNC) chez le sujet âgé
    Disease: Version SOC Term Classification Code Term Level
    8.1 10007953 Lymphome Primitif du Système Nerveux Central PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-003080-45 Sponsor Protocol Number: BRD/07/005 Start Date*: 2008-07-11
    Sponsor Name:University College London
    Full Title: Phase ll study evaluating the toxicity and efficacy of a modified German Paediatric Hodgkin's Lymphoma protocol (HD95) in young adults (aged 18-30 years) with Hodgkin's Lymphoma
    Medical condition: Medical condition under investigation is known as Hodgkin's disease, which is a cancer of the lymphatic system. It is usually treated with either chemotherapy or radiotherapy or a combination of bo...
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10020328 Hodgkin's lymphoma LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2017-003689-28 Sponsor Protocol Number: BrEPEM-LH-22017 Start Date*: 2018-04-05
    Sponsor Name:GELTAMO (Grupo Español de Linfomas y trasplante autólogo de médula osea)
    Full Title: A Phase Ib/II Trial of Combined SGN-35 (BrentuximabVedotin) Therapy with cyclophosphamide, procarbazine, prednisone, etoposide and mitoxantrone (BrEPEM) for Older Patients with Untreated Hodgkin Ly...
    Medical condition: Older Patients with Untreated Hodgkin Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004864 10080208 Classical Hodgkin lymphoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-001181-10 Sponsor Protocol Number: P003077 Start Date*: 2023-04-13
    Sponsor Name:Medical Center - University of Freiburg
    Full Title: Age-adjusted high-dose chemotherapy followed by autologous stem cell transplantation or conventional chemotherapy with R-MP as first-line treatment in elderly primary CNS lymphoma patients – a rand...
    Medical condition: Primary diffuse large B-cell lymphoma of the central nervous system (PCNSL) is a rare lymphoma affecting only the central nervous system compartment. PCNSL patients are typically 60 years or older ...
    Disease:
    Population Age: Elderly Gender: Male, Female
    Trial protocol: AT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-003116-12 Sponsor Protocol Number: IELSG45 Start Date*: 2019-11-01
    Sponsor Name:International Extranodal Lymphoma Study Group - IELSG
    Full Title: RANDOMIZED PHASE II TRIAL ON FITNESS AND COMORBIDITY - TAILORED TREATMENT IN ELDERLY PATIENTS WITH NEWLY DIAGNOSED PRIMARY CNS LYMPHOMA (FIORELLA Trial)
    Medical condition: Patients with newly diagnosed primary central nervous system lymphoma with age ≥70 years old
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10007953 Central nervous system lymphoma PT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended) FI (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-001104-21 Sponsor Protocol Number: ND-05006 Start Date*: 2009-01-28
    Sponsor Name:VU Cancer Centre, Afdeling Geneeskundige Oncologie
    Full Title: A PHASE I/II TRIAL OF A CONDITIONALLY REPLICATION-COMPETENT ADENOVIRUS (DELTA-24-RGD) ADMINISTERED BY CONVECTION ENHANCED DELIVERY IN PATIENTS WITH RECURRENT GLIOBLASTOMA MULTIFORME
    Medical condition: Recurrent Glioblastoma Multiforme
    Disease: Version SOC Term Classification Code Term Level
    9.1 10018337 Glioblastoma multiforme LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-005004-14 Sponsor Protocol Number: IEO S319/506 Start Date*: 2006-12-29
    Sponsor Name:ISTITUTO EUROPEO DI ONCOLOGIA
    Full Title: A phase II study about the use of intensified hybrid chemotherapy regimen ChLVVP/ABVVP in advanced Hodgkin lymphoma patients.
    Medical condition: Hodgkin s disease
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020243 Hodgkin's disease NEC HLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2016-000167-16 Sponsor Protocol Number: DIRECT-2016 Start Date*: 2016-05-19
    Sponsor Name:Sahlgrenska University Hospital
    Full Title: DIsulfiram REsponse as add-on to ChemoTherapy in recurrent Glioblastoma: A randomized controlled trial
    Medical condition: Glioblastoma
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018336 Glioblastoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) NO (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-006064-30 Sponsor Protocol Number: UCL/07/146 Start Date*: 2008-04-09
    Sponsor Name:University College London
    Full Title: A randomised phase III trial to assess response adapted therapy using FDG-PET imaging in patients with newly diagnosed, advanced Hodgkin Lymphoma
    Medical condition: Medical condition under investigation is Hodgkin Lymphoma, which is a cancer of the lymphatic system. It is usually treated with either chemotherapy or radiotherapy or a combination of both.
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004864 10020328 Hodgkin's lymphoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) IT (Ongoing) IE (Completed) SE (Completed) DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-001244-95 Sponsor Protocol Number: MK-3475-C11 Start Date*: 2021-07-30
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: Phase 2 Study of Pembrolizumab and Chemotherapy in Patients With Newly Diagnosed Classical Hodgkin Lymphoma (KEYNOTE-C11)
    Medical condition: Classical Hodgkin Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004864 10080208 Classical Hodgkin lymphoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) FR (Trial now transitioned) PL (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2010-022844-19 Sponsor Protocol Number: Start Date*: Information not available in EudraCT
    Sponsor Name:CHU de Dijon
    Full Title: Randomized phase III study of a treatment driven by early PET response compared to a treatment not monitored by early PET in patients with Ann Arbor Stage III-IV or high risk IIB Hodgkin lymphoma
    Medical condition: Hodgkin Lymphoma not previously treated
    Disease: Version SOC Term Classification Code Term Level
    12.1 10020328 Hodgkin's lymphoma LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: FR (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2019-004053-91 Sponsor Protocol Number: CO19/121741 Start Date*: 2020-07-06
    Sponsor Name:University of Leeds
    Full Title: Brain Re-Irradiation Or Chemotherapy: a phase II randomised trial of re-irradiation and chemotherapy in patients with recurrent glioblastoma
    Medical condition: Recurrent Glioblastoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018336 Glioblastoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2018-005027-16 Sponsor Protocol Number: NOA-18 Start Date*: 2020-09-16
    Sponsor Name:Heidelberg University Hospital Represented in law by its Commercial Managing Director
    Full Title: Improvement of functional Outcome for patients with newly diagnosed grade 2 or 3 glioma with co-deletion of 1p/19q - IMPROVE CODEL: the NOA-18 trial
    Medical condition: WHO grade 2 or 3 glioma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018338 Glioma PT
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10030288 Oligodendroglioma malignant LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2008-007645-31 Sponsor Protocol Number: 00591 Start Date*: 2009-06-23
    Sponsor Name:University Medical Center Freiburg
    Full Title: Freiburger Studie zur Behandlung von Primären ZNS-Lymphomen bei Patienten über 65 Jahre: Methotrexat-basierte Chemo-Immuntherapie mit anschließender Erhaltungstherapie - PRIMAIN-Studie -
    Medical condition: Patients with primary CNS Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004864 10036685 Primary central nervous system lymphoma LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2007-005920-34 Sponsor Protocol Number: Uni-Koeln-1014 Start Date*: 2011-10-14
    Sponsor Name:University of Cologne
    Full Title: HD17 for Intermediate Stage Hodgkin Lymphoma - Treatment Optimization Trial in the First-Line Treatment of intermediate Stage Hodgkin lymhoma; Therapy stratification by means of FDG-PET
    Medical condition: Hodgkin Lymphoma intermediate stage
    Disease: Version SOC Term Classification Code Term Level
    20.0 10005329 - Blood and lymphatic system disorders 10025319 Lymphomas Hodgkin's disease HLGT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) NL (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2017-004140-38 Sponsor Protocol Number: P160923J Start Date*: 2018-12-14
    Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
    Full Title: A phase II study from the POLA national network of nivolumab for recurrent IDH mutated High-Grade Gliomas
    Medical condition: Adults with recurrent IDH mutated high grade gliomas (IDHm HGGs)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018338 Glioma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-002584-25 Sponsor Protocol Number: 69HCL18_0132 Start Date*: 2019-02-04
    Sponsor Name:HOSPICES CIVILS DE LYON
    Full Title: A phase II study of olaparib in recurrent IDH mutated high grade gliomas OLAGLI
    Medical condition: patients with recurrent IDHm HGGs.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018338 Glioma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-003632-23 Sponsor Protocol Number: IC2019-02 Start Date*: 2020-06-17
    Sponsor Name:Institut Curie
    Full Title: LOC-R01: Randomized Phase IB/II Study of escalating doses of Lenalidomide and Ibrutinib in association with R-MPV as a targeted induction treatment for patients aged 18 to 60 with a newly diagnosed...
    Medical condition: Primary Central Nervous System Lymphoma (PCNSL) in patients aged 18 to 60, in first-line treatment
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10036685 Primary central nervous system lymphoma LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 11 17:36:54 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA